Anavex Life Science reported that its drug blarcasemine met primary endpoints in a late-stage trial for Alzheimer's disease.
3 reports, 3 independent
Updated Aug 1
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Anavex Life Science reported that its drug blarcasemine met primary endpoints in a late-stage trial for Alzheimer's disease.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaAnavex’s blarcasemine nets win in Phase IIb/III Alzheimer’s extension study In another potential win for patients with early-stage Alzheimer’s disease, Anavex Life Science’s precision medicine blarca
- BenzingaAnavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months Anavex Life Sciences Corp. (NASDAQ:AVXL) announced the latest findings on Thursday for blarcamesine, an or
- GlobeNewswireAnavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease New clini